GVL response patterns as defined by MRD kinetics
| Pattern . | pattern description . | n (%) . | Patients with chronic GVHD (% of patients of pattern at risk for chronic GVHD) . | Clinical relapses (% of all patients of pattern) . |
|---|---|---|---|---|
| 0 | Unclassifiable* | 9 (17) | 3 of 7 (43) | 2 of 9 (22) |
| 1 | MRD− immediately after SCT | 11 (21) | 6 of 8 (75) | 1 of 11 (9) |
| 2 | MRD− after immunosuppression tapering | 21 (40)† | 18 of 20 (90)† | 2 of 21 (10)† |
| 3 | MRD− after DLI | 2 (4) | 1 of 2 (50) | 1 of 2 (50) |
| 4 | No MRD response | 4 (8) | 1 of 4 (25) | 3 of 4 (75) |
| 5 | Incomplete and transient MRD response upon immunosuppression tapering | 5 (10)† | 5 of 5 (100)† | 3 of 5 (60)† |
| Total | 52 (100) | 34 of 46 (74) | 12 of 52 (23) |
| Pattern . | pattern description . | n (%) . | Patients with chronic GVHD (% of patients of pattern at risk for chronic GVHD) . | Clinical relapses (% of all patients of pattern) . |
|---|---|---|---|---|
| 0 | Unclassifiable* | 9 (17) | 3 of 7 (43) | 2 of 9 (22) |
| 1 | MRD− immediately after SCT | 11 (21) | 6 of 8 (75) | 1 of 11 (9) |
| 2 | MRD− after immunosuppression tapering | 21 (40)† | 18 of 20 (90)† | 2 of 21 (10)† |
| 3 | MRD− after DLI | 2 (4) | 1 of 2 (50) | 1 of 2 (50) |
| 4 | No MRD response | 4 (8) | 1 of 4 (25) | 3 of 4 (75) |
| 5 | Incomplete and transient MRD response upon immunosuppression tapering | 5 (10)† | 5 of 5 (100)† | 3 of 5 (60)† |
| Total | 52 (100) | 34 of 46 (74) | 12 of 52 (23) |
alloSCT indicates allogeneic stem cell transplantation; DLI, donor lymphocyte infusions; GVHD, graft-versus-host disease; GVL, graft-versus-leukemia; MRD−, negative minimal residual disease; and SCT, stem cell transplantation.
Early death, nonengraftment, or MRD− before alloSCT.
Patterns with clear evidence of MRD response to immunomodulation.